Alexion Pharma (ALXN) Tops Q4 EPS by 32c, FY EPS Guidance Beats

Alexion Pharma (NASDAQ: ALXN) reported Q4 EPS of $2.14, $0.32 better than the analyst estimate of $1.82. Revenue for the quarter came in at $1.13 billion versus the consensus estimate of $1.06 billion.

GUIDANCE:

Alexion Pharma sees FY2019 EPS of $9.10-$9.30, versus the consensus of $8.73. Alexion Pharma sees FY2019 revenue of $4.625-4.7 billion, versus the consensus of $4.75 billion.

For earnings history and earnings-related data on Alexion Pharma (ALXN) click here.

You May Also Be Interested In

• BofA raises AMD target to $720, sees server CPU TAM tripling to $211B by 2030
• General Mills (GIS) Tops Q1 EPS by 3c
• Moody’s raises BJ’s Wholesale outlook to positive on debt reduction